Antibody Discovery CRO
In Vivo & In Vitro
One Accountable Path
Whether you’re pursuing monoclonal antibody discovery for a novel therapeutic target or need a partner for end-to-end therapeutic antibody discovery, Mosaic brings the platforms, expertise, and integrated analytics to move fast without cutting corners. From immunization to lead selection, every program is built around your biology.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.
Integrated Discovery
In Vivo, In Vitro,
and Everything Between
In Vivo
Discovery
Immunization campaigns across humanized / transgenic mice (Atlas™ FHD), wild-type strains, hyperimmune models, and camelids for VHH/nanobody discovery
In Vitro Discovery & Optimization
Naive Fab and VHH libraries, phage display for epitope breadth, yeast display for affinity maturation and liability reduction
NGS-Driven Repertoire Mining
CDR3 diversity, clonal lineage tracing, and somatic hypermutation data to inform hit triage
Function-First Analytics
Early developability screening, binding kinetics, epitope mapping, and cell-based functional assays embedded throughout
Mosaic offers exclusive access to the Atlas™ FHD transgenic platform,, which delivers human-like repertoires with broad epitope coverage, available through milestone-based, royalty-free access.
Decision-Ready Deliverables
Every program delivers a complete data package including rank-ordered antibody leads, binding kinetics, epitope mapping, specificity profiling, expression and stability data, developability metrics, and a clear path to candidate selection. Lead panels from in vivo campaigns in 3–4 months.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
VP Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Ready to Start Your Antibody Discovery Program?
Tell us about your target and timeline. Our scientific team responds within one business day.
Start a conversation with our scientific team about your discovery program today